FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913522057> ?p ?o ?g. }

• W2913522057 endingPage "3293" @default.
• W2913522057 startingPage "3293" @default.
• W2913522057 abstract "Abstract Background: Bortezomib is a proteasome inhibitor that can lead to cell-cycle arrest and apoptosis. Bortezomib-based regimens are widely used as induction therapy of multiple myeloma (MM). Unlike lenalidomide (an immunomodulatory drug), the role of bortezomib in the consolidation and maintenance therapy of multiple myeloma is less clear. This study aims to examine the efficacy and safety of bortezomib-based regimens as consolidation/maintenance therapy in MM patients following induction therapy with or without autologous stem cell transplantation (ASCT). Methods: PubMed, ASH, and ASCO databases were searched for randomized controlled trials (RTC) of bortezomib-based regimens (either single-agent or combination) as consolidation/maintenance therapy for MM patients through July 2018. Study endpoints included overall survival (OS), progression-free survival (PFS), and adverse events (AE). Pooled hazard ratios (HR) for survival outcomes and relative risks (RR) for dichotomous data with 95% confidence interval (CI) were calculated with a random effect model using MedCalc (MedCalc Software, Ostend, Belgium). For studies that did not report HRs for survival outcomes but provided graphical survival curves, the log HRs and variances were estimated based on the method by Parmar et al (Stat Med 1998; 17: 2815-2834). Heterogeneity was assessed using the I2 statistic of inconsistency, with statistically significant heterogeneity defined as I2 > 50% or p-value < 0.1. Results: Eight randomized controlled trials (7 phase III, 1 phase II; 2 were published in a single article) were identified. Bortezomib-based regimens were administered as consolidation treatment in 5 RTCs and maintenance therapy in 3 RTCs, following induction therapy +/- ASCT. A total of 2439 patients were included: 1154 patients received bortezomib-based regimens, and 1285 patients received non-bortezomib-based regimens or observation. Two RCTs (1 for consolidation, 1 for maintenance) did not provide HRs, which were estimated as described as above. Pooled data from the 8 RCTs showed that bortezomib-based consolidation/maintenance therapy improved progression-free survival (HR 0.71, 95% CI 0.64-0.79, P < 0.001; I2 = 6.61%) and overall survival (HR 0.80, 95% CI 0.68-0.94, P = 0.005; I2 = 0%) compared to observation or regimens without bortezomib. When the 2 RCTs that did not report HRs were excluded from the meta-analysis, it did not alter the favorable outcome of bortezomib-based consolidation/maintenance therapy: PFS (HR 0.70, 95% CI 0.60-0.82, P < 0.001; I2 = 40.54%) and OS (HR 0.76, 95% CI 0.64-0.91, P = 0.002; I2 = 0%). The PFS benefit was maintained in a subgroup analysis by the setting of treatment (consolidation, HR 0.73, 95% CI 0.63-0.85, P < 0.001; I2 = 0%, maintenance, HR 0.70, 95% CI 0.56-0.0.86, P = 0.001; I2 = 55.63%). Bortezomib-based therapy prolonged OS in the maintenance setting (HR 0.71, 95% CI 0.58-0.86, P < 0.001; I2 = 0%) but not in the consolidation setting (HR 1.01, 95% CI 0.77-1.33, P = 0.935; I2 = 0%). Regarding safety, bortezomib-based consolidation/maintenance therapy significantly increased the risk of grade 3 or 4 peripheral sensory neuropathy and neuralgia (RR 2.09, 95% CI 1.11-3.95, p = 0.022; I2 = 52.64%) compared to observation or regimens without bortezomib. There was a trend toward increased rates of grade 3 or 4 thrombocytopenia (RR 1.54, 95% CI 0.95-2.52, p = 0.08; I2 = 21.67%), GI symptoms (RR 2.54, 95% CI 0.63-10.25, p = 0.19; I2 = 76.72%), vascular events (RR 1.90, 95% CI 0.80-4.53, p = 0.15; I2 = 0.00%), and fatigue (RR 2.10, 95% CI 0.83-5.30, p = 0.12; I2 = 0.00%) with bortezomib-based consolidation/maintenance, but these did not reach statistical significance. Conclusions: Bortezomib-based consolidation/maintenance significantly improves PFS and OS in MM patients following induction therapy +/- ASCT. The OS benefit appears to be limited to the maintenance setting based on a subgroup analysis. Bortezomib-based regimen increases the risk of grade 3 or 4 peripheral sensory neuropathy and neuralgia. Disclosures Bachanova: Gamida Cell: Research Funding; GT Biopharma: Research Funding; Kite Pharma: Membership on an entity's Board of Directors or advisory committees." @default.
• W2913522057 created "2019-02-21" @default.
• W2913522057 creator A5038008601 @default.
• W2913522057 creator A5052270984 @default.
• W2913522057 creator A5067489954 @default.
• W2913522057 creator A5084167089 @default.
• W2913522057 creator A5087453914 @default.
• W2913522057 date "2018-11-29" @default.
• W2913522057 modified "2023-09-30" @default.
• W2913522057 title "Bortezomib-Based Consolidation/Maintenance Therapy for Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials" @default.
• W2913522057 doi "https://doi.org/10.1182/blood-2018-99-113533" @default.
• W2913522057 hasPublicationYear "2018" @default.
• W2913522057 type Work @default.
• W2913522057 sameAs 2913522057 @default.
• W2913522057 citedByCount "0" @default.
• W2913522057 crossrefType "journal-article" @default.
• W2913522057 hasAuthorship W2913522057A5038008601 @default.
• W2913522057 hasAuthorship W2913522057A5052270984 @default.
• W2913522057 hasAuthorship W2913522057A5067489954 @default.
• W2913522057 hasAuthorship W2913522057A5084167089 @default.
• W2913522057 hasAuthorship W2913522057A5087453914 @default.
• W2913522057 hasBestOaLocation W29135220571 @default.
• W2913522057 hasConcept C126322002 @default.
• W2913522057 hasConcept C141071460 @default.
• W2913522057 hasConcept C143998085 @default.
• W2913522057 hasConcept C168563851 @default.
• W2913522057 hasConcept C197934379 @default.
• W2913522057 hasConcept C207103383 @default.
• W2913522057 hasConcept C2776063141 @default.
• W2913522057 hasConcept C2776364478 @default.
• W2913522057 hasConcept C2776694085 @default.
• W2913522057 hasConcept C2777478702 @default.
• W2913522057 hasConcept C2778283404 @default.
• W2913522057 hasConcept C44249647 @default.
• W2913522057 hasConcept C71924100 @default.
• W2913522057 hasConceptScore W2913522057C126322002 @default.
• W2913522057 hasConceptScore W2913522057C141071460 @default.
• W2913522057 hasConceptScore W2913522057C143998085 @default.
• W2913522057 hasConceptScore W2913522057C168563851 @default.
• W2913522057 hasConceptScore W2913522057C197934379 @default.
• W2913522057 hasConceptScore W2913522057C207103383 @default.
• W2913522057 hasConceptScore W2913522057C2776063141 @default.
• W2913522057 hasConceptScore W2913522057C2776364478 @default.
• W2913522057 hasConceptScore W2913522057C2776694085 @default.
• W2913522057 hasConceptScore W2913522057C2777478702 @default.
• W2913522057 hasConceptScore W2913522057C2778283404 @default.
• W2913522057 hasConceptScore W2913522057C44249647 @default.
• W2913522057 hasConceptScore W2913522057C71924100 @default.
• W2913522057 hasIssue "Supplement 1" @default.
• W2913522057 hasLocation W29135220571 @default.
• W2913522057 hasOpenAccess W2913522057 @default.
• W2913522057 hasPrimaryLocation W29135220571 @default.
• W2913522057 hasRelatedWork W1966525515 @default.
• W2913522057 hasRelatedWork W1986021912 @default.
• W2913522057 hasRelatedWork W2000304045 @default.
• W2913522057 hasRelatedWork W2033089666 @default.
• W2913522057 hasRelatedWork W2072770520 @default.
• W2913522057 hasRelatedWork W2090603150 @default.
• W2913522057 hasRelatedWork W2150885028 @default.
• W2913522057 hasRelatedWork W2496924072 @default.
• W2913522057 hasRelatedWork W2801448674 @default.
• W2913522057 hasRelatedWork W4362657670 @default.
• W2913522057 hasVolume "132" @default.
• W2913522057 isParatext "false" @default.
• W2913522057 isRetracted "false" @default.
• W2913522057 magId "2913522057" @default.
• W2913522057 workType "article" @default.